" class="no-js "lang="en-US"> James McKim - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
James McKim

James McKim

About James McKim

Doctorate of Philosophy (Ph.D.) in Biochemical and Molecular Toxicology from Oregon State University.

Group leader at Dow Corning Corporation, leading research aimed at understanding the biological impact of siloxanes.

Diplomat of the American Board of Toxicology since 1995.

Research Advisor at Pharmacia, developed and managed the in vitro screening laboratory. Co-Invented and developed an in vitro screening method to predict the plasma concentration at which toxicity would be expected to occur in animals studies. Received full patent in the US and EU.

Related Story

Drug Development

 LifeNet Health LifeSciences Launches New

LifeNet Health LifeSciences Launches New, Human-relevant Cell-based Assay Service for Drug and Compound Discovery

August 2 2022

LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, is launching a new Cell-Based […]